UBS Initiates Coverage on Viking Therapeutics With Buy Rating and $94 Target
Yahoo Finance ·
On October 14, UBS initiated coverage of Viking Therapeutics with a buy rating and a 12-month price target of $94 assigned by analyst Joon Lee. With the shares trading near $26.75, the target implies an upside potential of roughly 250%. UBS highlights that Viking's experimental weight loss drug, VK2735, could achieve significantly greater fat reduction than current market leaders, pointing to clinical data suggesting outcomes roughly twice those of semaglutide and 1.5 times those of tirzepatide. VK2735 targets both GLP-1 and GIP hormones, mirroring the dual-agonist mechanism of Eli Lilly's Zepbound, whereas Novo Nordisk's Wegovy focuses solely on GLP-1. In the Phase 2 Venture trial, the injectable treatment delivered up to 14.7% average weight loss after 13 weekly doses. Furthermore, September data from roughly 180 obese adults showed 16% to 19% reductions after 21 weeks, with an extended exploratory cohort reaching an average decrease of 21.7% at 33 weeks.
AI 시장 분석
UBS initiated coverage on Viking Therapeutics with a Buy rating and a price target of $94, suggesting about 250% upside from the current price, driven mainly by clinical data for its experimental obesity treatment VK2735. Investors should monitor late-stage clinical results and future market competition.
상승 영향
- Biotechnology — Viking Therapeutics' drug candidate VK2735 recorded superior weight loss clinical data compared to existing obesity treatments, raising earnings expectations.
DYAX 전담 분석
Viking Therapeutics' drug candidate VK2735 showed a maximum weight loss of 14.7% in just 13 weeks during Phase 2 trials, and recently recorded a 21.7% reduction at week 33. This is evaluated as an outstanding performance compared to existing treatments, driving a surge in the company's value.
While further stock surges are possible depending on upcoming large-scale late-stage clinical results, market defense strategies by competitors Eli Lilly and Novo Nordisk remain key risk factors.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 44% · Bearish (Short) 56%
365 participants
Related News
- Binance Faces $3.64B Outflows and Federal Probe Following Security Breach
- The Top Five News Show Debuts on Apple Podcasts and Spotify
- Lumen and Microsoft Deepen Partnership to Accelerate Enterprise AI-Ready Network Sales
- Historic $6.3 Billion Binance Hack Shakes the Cryptocurrency Market
- GEO Group Stock Jumps 4% Following $2 Billion Texas ICE Contract Award
- Why IDEXX Laboratories Shares Surged Today
